Basilea Pharmaceutica

Company snapshot

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in the heart of the life sciences hub of Basel area, Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands: Cresemba for the treatment of invasiv

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 25 US patent(s) indexed to this assignee profile.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Basilea Pharmaceutica. Not investment advice.

• What is Basilea Pharmaceutica?

  Basilea Pharmaceutica is a pharma organization headquartered in Allschwil, CH. Primary therapeutic focus areas include Gastric Adenocarcinoma. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials

• Is Basilea Pharmaceutica publicly traded?

  Basilea Pharmaceutica appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Basilea Pharmaceutica develop or market?

  We link 3 drug profile(s) where Basilea Pharmaceutica is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/basilea-pharmaceutica-deutschland-gmbh#company-drugs.

• What are the latest developments for Basilea Pharmaceutica?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Basilea Pharmaceutica focus on?

  Basilea Pharmaceutica focuses on Gastric Adenocarcinoma based on our analysis of their pipeline programs and drug development activities.